![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi’s Dupixent Gets Priority Review
Sanofi’s Dupixent Gets Priority Review
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
March 14, 2019
The FDA granted priority review status to Sanofi’s Dupixent (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP).
There are no current FDA-approved biologics to treat the condition. The supplemental BLA is supported by data from two Phase 3 trials assessing its efficacy combined with standard corticosteroid nasal spray.
Dupixent is already approved for treatment of adults with moderate-to-severe eczema and for use with other asthma drugs for the maintenance treatment of moderate-to-severe asthma.
Upcoming Events
-
21Oct